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Abstract 
Paraoxonase I (PON1) is a serum hydrolase that has been found to hydrolyze 
organophosphates (OP), such as VX and sarin.  Because human PON1 (huPON1) is a human 
protein with reasonable activity, it seems like a promising therapeutic agent against OP 
poisoning.  However, huPON1 is an insoluble protein and not very stable when expressed in E. 
coli, whereas a chimeric mammalian PON1 variant, G2E6, has proven to be soluble and 
expressible in E. coli.  We are specifically working on a way to make huPON1 more soluble by 
using a rational approach of changing a cluster of hydrophobic residues on the surface of the 
protein into polar ones.  Since these mutations are on the surface of the protein, it is rationalized 
that it may not significantly affect the activity of huPON1. 
 We are employing two different rational designs to make huPON1 more soluble.  The 
first strategy utilizes a three fragment PCR overlap containing 12 hydrophobic residues from the 
HDL binding site that are mutated to polar residues.  The second design utilizes total gene 
synthesis in order to make 16 hydrophobic to polar residues in huPON1 corresponding to the 
G2E6 mutations that are polar.  These variants were put into a vector containing folding reporter 
GFP to screen for solubility and expression by means of cellular fluorescence.  We have been 
able to express both variants and have observed them to be significantly more soluble than the 
wild-type one. 
 In order to achieve even more solubility, we have fused these huPON1 variants with 
Maltose Binding Protein (MBP) which has been shown to improve the solubility of many 
proteins.  By doing this, we have been able to express and purify large amounts of protein in 
order to obtain biophysical characteristics.  Both huPON1 variants prove to be active against 
paraoxon and phenyl acetate. 
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Introduction 
 
Organophosphate Background 
Organic phosphorous (OP) compounds have been developed for their effectiveness as 
insecticides.  However, because the mammalian and insect cholinergic nervous systems are 
similar, these compounds have been responsible for millions of poisonings and thousands of 
deaths annually.
1
  These OP compounds target acetylcholinesterase, a β-esterase that hydrolyzes 
acetylcholine, a neurotransmitter, into acetate and choline.
1
  If acetylcholinesterase is inhibited, 
acetylcholine will accumulate in the synaptic clefts, causing a cholinergic over-stimulation.
1
  
This over-stimulation leads to cholinergic syndrome which includes increased sweating and 
salivation, bronchial secretion, bronchoconstriction, increased gastrointestinal motility, tremors, 
muscular twitching, and other central nervous system activities.
1
  Because of these known toxic 
affects, OP derivatives have been developed that are more toxic for use in chemical warfare.  
These nerve agents, such as soman (GD), sarin (GB), tabun (GA), cyclosarin (GF) and VX and 
Russian VX (VR), have already been used in the Iraq-Iran war (1983-1988) and in terrorist 
attacks in Matsumoto (1994) and Tokyo (1995).
2
  
 
 
Figure 1. Nerve Agent Structures along with 
Phenyl Acetate and Paraoxon which are used to 
test activity of huPON1 and its variants. 
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Pharmacological treatment for these OPs has not been very effective to date, mainly 
because treatment is done post-exposure.  Some therapies that are being utilized are 
anticonvulsants, acetylcholine receptor antagonists and oximes, but they are not able to directly 
detoxify the nerve agents in vivo.
3
  Atropine sulfate, an anticholinergic drug, has been one of the 
main treatments of OP poisoning,
4
 but only treats neurological and not systemic effects.  To treat 
OP poisoning prophylactically, before the nerve agent reaches the synapse, would be more 
effective in blocking the antiacetylcholinesterase activity of OP agents. 
A human protein that is capable of hydrolyzing organophosphates before, during, and 
after exposure has been found, although it is too slow in hydrolysis of OPs to be of therapeutic 
importance.  In principle, a catalytic protein would be useful because it will take a small amount 
of enzyme to detoxify large amounts of nerve agent in circulation without being consumed, thus 
being able to protect against multiple exposures.
3
  However, challenges to create a useful 
therapeutic enzyme do arise.  The enzyme must be produced in large amounts, has to be active 
against a large spectrum of OPs, must be able to be kept under various conditions without loss of 
activity, has to possess no immunological side effects, and needs to be delivered into the system 
through intramuscular or intravenous injection.
2
 
HuPON1 
The protein of interest in developing a therapeutic agent against organophosphate 
compounds comes from the human paraoxonase (PON) gene family.  This family consists of 
PON1, PON2, and PON3, with PON1 being the most extensively studied due to its 
esterase/lactonase activity, as well as its anti-atherogenic activity.
5, 6
  Human Paraoxonase I 
(huPON1) is a glycosylated protein composed of 354 amino acids (43-47 kDa).
5
  The crystal 
structure of huPON1 has not yet been determined, and so the exact mechanism of the active site 
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is not known.  A recombinant PON1, known as G2E6, has been engineered by randomly 
combining rabbit, mouse, rat, and human PON1 genes, and for this, a crystal structure has been 
obtained giving us an idea of the structure of huPON1.  PON1 is described as a six-bladed β-
propeller, with each blade consisting of four β-strands.2 It is a calcium-dependent enzyme, with 
the central calcium required to maintain structural integrity while the “top” one is essential for 
enzymatic activities.
2, 3
 
HuPON1 is synthesized in the liver and is bound to high density lipoprotein (HDL) 
particles in circulation, presumably via three α-helices located at the top of the propeller.2  
Because of this association with HDL, it is believed that huPON1 plays a role in protecting 
against atherosclerosis.  This has been a much studied topic of late as it may prevent or limit 
oxidation of low-density lipoproteins (LDL).
6
  For our purpose, the HDL binding site is full of 
hydrophobic residues which may be a reason why huPON1 is insoluble when expressed in E. 
coli.   
Using a microbial system to over-express proteins of interest, usually E. coli, has proven 
to be an effective method in expressing and characterizing recombinant human proteins for 
human therapeutic use.  However, E. coli tends to express heterologous proteins in an insoluble 
form, causing the proteins to aggregate.
7
  Some conventional methods to obtain a soluble and 
correctly folded target protein include:  low temperature expression, promoters with varying 
strengths, and solubility-enhancing fusion tags.
8
  An alternative method is site-directed rational 
mutations to improve the folding, stability, and solubility.
8
  We have combined the conventional 
strategy of using fusion tags, green fluorescent protein (GFP) and maltose binding protein 
(MBP), with rational engineering of huPON1in order to obtain greater solubility. 
 
9 
 
frGFP Fusion 
 Green fluorescent protein (GFP) fusion can be used to report the folding of the protein of 
interest.  The protein of interest is expressed as an N-terminal fusion with folding reporter GFP 
(frGFP), and if the target protein folds correctly, a chromophore will form from GFP and 
fluoresce in the green.
9
  If the target protein does not fold correctly, then GFP will not fold and 
no fluorescence will be seen (Figure 2).  Waldo and co-workers expressed a test panel of 20 
proteins and examined their solubilities by SDS-PAGE before measuring the whole-cell 
fluorescence of these test proteins as GFP fusions.  The results show that the folding of GFP and 
formation of the chromophore is directly related to the folding of the upstream protein.  The 
frGFP was then used to isolate soluble 
variants of proteins that aggregate when 
expressed in E. coli to show a fluorescence 
signal that is proportional to the amount of 
correctly folded protein.
9, 10
  Using this 
reporter method, we can quickly find 
which rational design mutants of huPON1 
are soluble when over-expressed in E. coli. 
 
MBP Fusion 
 Soluble fusion tags have been shown to help decrease the aggregation of insoluble 
chimeric proteins when over-expressed in bacteria and eukaryotic systems.
11
  When compared 
with two other soluble fusion partners, maltose binding protein (MBP) proved to be far more 
effective in solubilizing the target protein.
12
  In order to see which soluble fusion protein gave 
the greatest overall solubility, Waugh and co-workers compared three soluble fusion tags: 
Figure 2. If the protein of interest misfolds, then frGFP will misfold 
and their will be no chromophore formation.  If the protein of 
interest folds correctly, GFP will fold correctly and their will be 
fluorescence.10 
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thioredoxin (TRX), glutathione 
S-transferase (GST), and 
maltose-binding protein (MBP).  
MBP was fused to the N-
terminal of six different 
insoluble proteins (TIMP, p16, 
E6, CATΔ9, GFP, TEV) when 
over-expressed in E. coli.  Each of the proteins were shown to have a greater solubility when 
expressed, and had a greater overall solubility than those fused with TRX and GST (Figure 3).  
The MBP fusion tag can be a worthwhile method in enhancing the solubility of our rational 
design mutants of huPON1 in E. coli. 
Molecular Chaperones 
 When trying to express human proteins in E. coli, they often become misfolded and 
deposited as insoluble inclusion bodies.
13
  In order to help achieve a more stable huPON1variant 
when expressed in E. coli, molecular chaperones can be co-expressed with our protein.  R. John 
Ellis defines molecular chaperones as, “proteins that assist the correct non-covalent assembly of 
other polypeptide-containing structures in 
vivo, but are not components of these 
assembled structures.”14  Protein folding 
attempts to bury hydrophobic residues in the 
interior of the protein while retaining polar or 
charged residues on the surface.  Chaperones 
act by helping direct the proper folding of the 
Figure 3. Comparison of solubilizing fusion tags TRX, GST, and MBP.12  
Figure 4. Chaperonin, a type of molecular chaperone that 
brings unfolded proteins into the cavity where the 
hydrophobic environment encourages proper folding.15 
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protein.  They can reform the protein when it aggregates; allowing it to then refold properly, and 
by binding to hydrophobic surface residues can help prevent further misfolding.
14, 15
  These 
hydrophobic surfaces can interact with similar surfaces in other proteins being expressed, leading 
to aggregation.  These molecular chaperones can be used to help refold huPON1 after expression 
in E. coli. 
Objective 
 
Increase Solubility and Stability of huPON1 
 
Expressing recombinant proteins in E. coli is a very efficient and cost effective method of 
producing human proteins for therapeutic use.  Wild-type huPON1 is able to be expressed in E. 
coli but with minimal to no protein in the soluble fraction.  Because of this, only a small amount 
of activity was reported for huPON1 after expression and purification.  The goal is to obtain a 
variant that closely resembles the human protein sequence in order to avoid an immune reaction 
when used as a therapeutic agent.  The idea of rational design of protein surface amino acids will 
be used to change hydrophobic residues on the surface into polar ones.  Two such mutants, the 
first mutating 12 hydrophobic residues from the HDL binding site into polar ones with equal 
numbers of lysine, glutamic acid, and glutamine; the second changing 16 hydrophobic to polar 
residues in huPON1 corresponding to the G2E6 mutations that are polar, should give more 
soluble variants without changing much of the activity.  Additional strategies to achieve greater 
solubility includes fusion of huPON1 with a solubility fusion tag, Maltose Binding Protein 
(MBP), deletion of the unstructured N-terminal hydrophobic residues in the mutants, and use of 
bacterial chaperones to help with the folding and stability. 
 
 
 
 
12 
 
Methods 
 
Rational mutations on HDL binding site of huPON1 
Gene Construction.  Oligonucleotides were purchased (Sigma-Genosys) to synthesize a 
gene with mutations of Phe24Glu, Tyr185Glu, Phe186Gln, Ile187Lys, Tyr190Lys, Leu191Gln, 
Trp194Lys, Leu198Glu, Leu200Gln, Trp202Lys, 
Met289Gln, Phe293Glu. The huPON1 variant with the 
mutations on the HDL binding site was constructed using 
a three fragment overlap PCR method.  Each fragment was 
designed to complementarily overlap with each other.  
Once each fragment was made (Fragments 1, 2, and 3), 
they were mixed together and the flanking primers, 5’ 
forward and Fragment 3 reverse, were added.  Another 
PCR was run to extend and amplify the entire gene.  The 
oligonucleotides used to form these twelve mutations are shown in Table 1.  
Table 1. Primers used for huPON1 HDL mutant gene construction 
Primer Sequence 
5’ forward ATAGATATAC ATATGGCGAA GCTGATTGCA CTCACGCTCT 
TGGGGATGGG ACTGGCACTC TTCAGGAACC ACC 
 
Fragment 1 
forward 
GGCACTC TTCAGGAACC ACC AGTCTTC AgaaCAAACA 
CGACTTAATG CTCTCCGAGA 
 
Fragment 1 
reverse 
CATCTCC TTGGATTGCT GCT TGGGGTC TTTTTGCTCG 
TGATCATTTG TGCCATAAAAGTG 
 
Fragment 2 
forward 
agcagCAATC CaagGAGATG TATgagGGTc aaGCGaaaTC GTATGTTGTC 
TACTATAGTC 
 
Fragment 2 
reverse 
CATACTCGAAGATTTTTTGTCCGTTAGGATGGCATCCAACCCAAAGG  
 
Figure 5. Mutations shown (in green) that were 
made on the HDL binding site 
13 
 
 
Rational G2E6 polar mutations in huPON1 
Gene Construction.  The second solubilizing variant was constructed by total gene 
synthesis using the TBIO method.
16
  Hydrophobic to 
polar residues were mutated from G2E6 to wild-type 
huPON1 using 30 primers containing 16 point 
mutations.  Fifteen of the mutations (I5T, N19R, Q21K, 
L31H, N78D, N80D, S81K, P82S, L96S, G101E, 
A137S, Q192K, Y197H, N265D, and N309D) were on 
the surface and an N166S compensatory mutation of 
Q192K were made.  The full length huPON1-G2E6 
polar gene was amplified using two flanking primers 
shown in Table 2.  
Table 2. Primers used for huPON1 G2E6 Polar mutant gene construction 
Primer Sequence 
Forward Terminal 
Primer 
GTTTAACTTTAAGAAGGAGATATACATATGGCAAAGCTGACCGC 
Reverse Terminal 
Primer 
TGAAAATACAGATTCTCACCGCCGGTACCTAATTCACAG 
 
Cloning mutants into pET11a-Null-frGFP vector 
The huPON1 variants: huPON1 HDL and huPON1 G2E6 polar, and the wild-type 
huPON1genes along with the pET11a-Null-frGFP vector with TEV- and His6-sites were digested 
with NdeI and EcoRI.  After overnight ligation at 16 
o
C, the plasmid with our gene of interest 
was transformed into electrocompetent DH10B cells.  These cells were recovered, plated on LB 
Fragment 3 
forward 
CT AACGGAcaaA AAATCTTCga gTATGACTCA GAGAATCCTCCTG  
 
Fragment 3 
reverse 
GCCCTTGCTCACGAATTCGCCGCCGCTTCC 
 
Figure 6. Polar residue mutations shown (in green) 
that  were mutated from G2E6 to huPON1 
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ampicillin plates and incubated overnight at 37 
o
C.  Colonies were picked and then grown in 
2YT media.  The DNA was extracted (Qiagen Miniprep) and sequenced (Genewiz). Once 
sequencing confirmed our huPON1 mutated genes of interest, they were transformed into 
electrocompetent Origami B cells for protein expression.   
Engineering mutants with MBP solubility fusion tag 
Gene Construction and Cloning. Each mutant was amplified with primers containing 
restriction sites for use with pHMT-MBP vector shown in Table 3.  The genes and pHMT-MBP 
vector were digested with NcoI and PstI.  Overnight ligation at 16 
o
C was followed by 
transformation into electrocompetent DH10B cells.  These were recovered and plated on LB 
ampicillin resistant plates and incubated overnight at 37 
o
C.  Picked colonies were grown in 2YT 
media, and the extracted DNA (Qiagen Miniprep) was sequenced (Genewiz). 
Table 3. Primers for MBP fusion tag 
Primer Sequence 
huPON1 fw AATAAT CCATGG GCTAA GCTGATTGCG CTCACCC 
 
huPON1 re AATAAT ctgcag TTA GAGTTCGCAaTAAA GAGCTTTGTGA 
AACACTGTGCC 
 
huPON1 HDL fw AATAAT gtcgac GCGAAGCTGATTGCACTCACGC 
 
huPON1 HDL re AATAAT ctgcag TTA GAGTTCGCAaTAAA GAGCTTTGTGA 
AACACTGTGCC 
 
huPON1 G2E6p fw AATAAT gtcgac GCAA AGCTGACCGC aCTGACTCTG TTAG 
GCATGG GTTTAGCAC 
 
huPON1 G2E6p re AATAAT ctgcag TTA 
TAATTCACAGTATAATGCTTTATGGAAAACCG 
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Re-engineering mutants with C-terminal His6-tag 
Gene Construction and Cloning. Oligonucleotides were purchased (Sigma-Genosys) 
containing C-terminal His6-tag and new restriction sites NcoI and XhoI to match restriction sites 
on pET11a-MBP vector shown in Table 4.  The genes were constructed using PCR and huPON1 
HDL gene as a template. 
Table 4. Primers for MBP fusion tag with C-terminal His6-tag 
Primer Sequence 
huPON1HDL fw AATAATAAT CCATG G GCGAAGCTG ATTGCACTCA CGCTCTTGG  
 
huPON1HDL re AATAATAAT CTCGAG TTA ATGATGATGATGATGATG 
GCCGCTACTTCC GAGTTCGCAGTAAAGAGCTTTGTGAAACAC 
 
huPON1G2E6p fw AATAATAATCCATGG GCAAAGCTG ACCGCGCTGA CTCTG  
 
huPON1G2E6p re AATAATAAT CTCGAG TTA ATGATGATGATGATGATG 
GCCGCTACTTCC TAATTCACAGTATAATGCTTTATGGAAAACC 
 
  
Expression and Purification.  The expression was done with 1 L of 2YT media 
containing ampicillin (100 g/mL), kanamycin (35 g/mL), and CaCl2 (1 mM) and grown at 37 
o
C.  It was then induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) after log 
phase of OD600  0.8 was reached, and then placed at 30 
o
C for 6 hrs.  The cells were centrifuged 
at 7,000 rpm for 5 min., and the harvested cell pellets were placed at -80 
o
C.  Cell lysis was 
performed by resuspending the pellet using lysis buffer (50 mM Tris-HCl, 200 mM NaCl, 10 
mM imidazole, 1 mM CaCl2, 0.1 mM MgCl2, pH 8.0) with RNase, DNase, lysozyme, DTT (2 
mM), and 10% glycerol, and then incubating on ice for 1 h.  Sonication helped with the final 
lysis of the pellet.  Tergitol (0.1%) was added and left on nutator for 2-3 hrs.  The clear cell 
lysate was collected after centrifugation and added to 1.5 mL of Ni-NTA resin.  After allowing 4 
hrs, or overnight binding of the protein, the lysate was run through the column.  It was then 
16 
 
washed with 20 mL of lysis buffer (2 mM DTT, 0.1 % Triton X-100, 10% glycerol) and then 30 
mL of wash buffer (50 mM Tris-HCl, 250 mM NaCl, 40 mM imidazole, 1 mM CaCl2, 10% 
Glycerol, 1 mM DTT, 0.1% Triton X-100).  The protein was eluted in 10 mL of elution buffer 
(50 mM Tris-HCl, 50 mM NaCl,150 mM imidazole, 1 mM CaCl2, 10% Glycerol, 0.1% Triton 
X-100).  The clear lysate, flow through, wash, and elution were loaded onto a 12.5% SDS-PAGE 
gel for analysis. 
Activity Assay.   A paraoxon activity assay was performed on the purified proteins 
by adding paraoxon (in 100% MeOH) at volumes of 0.4-4 L with 10 L of huPON1 enzyme in 
50 mM Tris-HCL, 10 mM CaCl2 buffer at pH 7.4 for a total reaction volume of 200 µL.  The 
hydrolysis of paraoxon was monitored at 405 nm absorbance for 30 min. 
Arylesterase activity was also performed using the same procedure as above only with 
phenyl acetate at volumes of 0.4-5 L and monitored at 270 nm absorbance for 1 min.  
Co-expression with Chaperones 
At the same time, our lab was exploring the use of chaperones to help in protein folding.  
It was found that the plasmid pKJE7, containing molecular chaperones DnaK, DnaJ, and GrpE, 
was the chaperone system of choice for huPON1 (Magliery, Shete, Competty).  The pKJE7 
plasmid was co-transformed into Origami B cells with the previously mentioned huPON1 
variants.   The expression and purification procedure was followed as above for the re-
engineered huPON1 mutants with C-terminal His6-tag.  However, chloramphenicol (30 g/mL) 
was added and L-arabinose (0.1%) was used as an inducer for the chaperones at the beginning of 
expression.  Once achieving log phase of OD600  8.0, IPTG (0.25 mM) was added.  Activity 
assays were performed using procedure followed above. 
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N-terminal Deletion 
The N-terminus of huPON1 and G2E6 contain a string of hydrophobic residues that may 
contribute to the insolubility of huPON1 in E. coli.  Residues 4-17 (LIALTLL GMGLALF ) in 
huPON1 HDL, huPON1 G2E6p, and wt-huPON, as well as in G2E6 (for comparison) were 
deleted in order to increase the solubility.  The PCR products were cloned, expressed, and 
purified using the same procedures outlined above.  
Results and Discussion 
Rational mutations on HDL binding site of huPON1 
 Figure 7 shows the schematic of the three piece overlap PCR that was used to obtain the 
12 mutations on the HDL binding site from hydrophobic amino acids to equal numbers of lysine, 
glutamic acid, and glutamine.  A comparison of the HDL mutant with G2E6 to show whether the 
rational design achieved 
greater solubility is shown 
in Figure 8.  In terms of 
wild-type huPON1, these 12 mutations succeeded in creating a variant with greater solubility.  
However, when compared with G2E6, the amount of protein expressed in the soluble fraction is 
somewhat less.  When a whole cell fluorescence of the GFP fusions of the huPON1 variants was 
done (Figure 9), huPON1 HDL was the third most soluble enzyme. The deletion variant of HDL 
proved to be the most fluorescent, correlating into a greater solubility than the other variants, 
including G2E6.  After testing the activity against paraoxon (Figure 10) to see if our surface 
mutations changed the interior chemistry, it was concluded that the HDL mutant had the greatest 
activity when comparing cell lysates, although down compared to G2E6.  The deletion mutant, 
Figure 7. Three piece overlap PCR method containing all 12 hydrophobic to polar 
mutations. 
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although more soluble, was less 
active.  This leads to the 
possibility that the N-terminus 
plays a role in determining 
activity. 
 In conclusion, rationally 
designing the HDL mutant led to a 
more soluble protein than 
huPON1, although less soluble than 
G2E6.  The enzyme was active against paraoxon, although less active than G2E6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. 12.5% SDS-PAGE gel comparing rationally designed huPON1 
HDL variant with recombinant huPON1, G2E6.  The clear lysate (CL), flow 
thru (FT), wash (W), and elution (E) of both are shown.  The highlighted 
bands indicate huPON1 HDL and G2E6 fused with frGFP (67 kD) 
Figure 9. Emission spectra of huPON1 variants fused with frGFP expressed in 
E. coli.  The solubility of the protein is highly correlated with fluorescence of 
E. coli expressing corresponding GFP fusions. 
19 
 
 
Rational G2E6 polar mutations in huPON1 
 The 16 mutations that are present in this variant caused the protein to become 
significantly more soluble when expressed in E. 
coli as shown by Figure 11.  This design, like the 
HDL mutant, still produced less of a yield than 
G2E6.  Upon whole cell fluorescence (Figure 9), 
the G2E6 polar mutant showed similar solubility 
levels as G2E6.  When tested against paraoxon, 
we can see that the protein is still active, although 
less active than G2E6 (Figure 10).  
Mutants with MBP solubility fusion tag 
 Figure 12 shows a comparison between the HDL and G2E6 polar mutants, as well as the 
deletion variants of wild-type huPON1 and the HDL variant when fused with MBP.  As 
hypothesized, the MBP fusion tag increased the solubility of all our variants a great deal.  
However, as can be seen by the gel, the proteins were not very pure.  It appeared that other 
Figure 11. Cell lysate activity assay against paraoxon. These mutants were expressed in Origami B. Cells were lysed using glass beads. 
20 L of clear lysate was used for the activity assay. A.) G2E6 and its deletion variant.  B.) huPON1 variants and their deletions. 
Figure 10. 12.5% SDS-PAGE gel comparing rationally 
designed huPON1 G2E6 polar variant with recombinant 
huPON1, G2E6 and wild-type huPON1.  The highlighted 
bands indicate our proteins fused with frGFP (67 kD) 
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proteins being expressed in E. 
coli were bound to the Ni-
NTA resin, even after 
rigorous attempts at 
optimization.  Figure 13 
shows that all mutants 
retained their activity against 
paraoxon. 
 The same bands were 
being retained on the gel consistently, even after the various purification conditions we subjected 
our protein to.  This led to the belief that they may be truncated products, a result that can occur 
from over-expression of non-native proteins in E. coli.  Because the His6-tag was connected to 
the N-terminus of the proteins, 
the truncated products can 
adhere to the Ni-NTA column.  
In order to definitively 
determine that these were in 
fact His6-tagged as well, a 
HisProbe Western blot was run 
(Figure 14), proving that the extra 
bands were from truncated product 
of our huPON1 genes.  To get rid of these extra products, we reengineered the vectors to have a 
C-terminal His6-tag fused to our huPON1 variants (Figure 15).   
Figure 12. 12.5% SDS-PAGE gel showing the elution products of huPON1 variants 
fused with MBP. 
Figure 13. Paraoxon activity assay of huPON1 variants fused with MBP and 
expressed in Origami B.  Absorbance was taken at 405 nm. 
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Reengineered C-terminal His6-tag co-expressed with chaperones 
 
At the same time as the reengineering of our vectors, our lab was exploring the use of 
molecular chaperones to help in the folding of 
huPON1 when expressed in E. coli.  Out of 
several different chaperone sets tested, DNA 
KJE7 (DnaK, DnaJ, and GrpE),
17
 was able to 
express some amount of active wild-type huPON1.  We speculated this might also be useful for 
our variants.  The DNA KJE7 vector and the reengineered C-terminal His6, MBP fusion huPON1 
and its variants were co-transformed and expressed with cleaner bands (Figure 16) and better 
yields (Table 5.).  All solubilizing variants were expressed in higher yields than wild-type 
huPON1, with the deletion variants producing more protein than their full length counterparts.  
All variants proved to be active against both phenyl acetate and paraoxon. 
Kinetics of huPON1 and its variants 
The kinetics, shown in Tables 6 and 7, of phenyl acetate and paraoxon hydrolysis of 
huPON1 and its variants show wild-type huPON1 to be more active compared to all of the other 
Figure 14. Western blot of HisProbe experiment of huPON1 
variants fused with MBP. 1-huPON1 HDL cell lysate; 2-3 huPON1 
HDL; 4-MBP; 5-huPON1 G2E6p; 6-∆huPON1 
Figure 15. Scheme showing how a reengineered C-terminal 
His6-tag was able to reduce the truncated products after protein 
purification with an N-terminal tag produced multiple eluted 
products 
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variants.  The N-terminal deletion 
mutants were less active than any 
of the full length mutants, 
indicating that the unstructured 
portion of the N-terminus may 
play a role in either activity or 
stability of the protein. 
 
 
 
 
Table 5. Concentrations (mg/L) of MBP fused huPON1 and its variants after reengineering the vector with a C-terminal His6-tag 
and co-expression with chaperone set DNA KJE7. 
 
 
Table 1. Kinetics data of huPON1 and its variants on the hydrolysis of phenyl acetate in mM min-1. 
Conclusion 
The study of huPON1both as a catalytic bioscavenger and as an insight into how proteins 
function has proven to be challenging yet very rewarding.  We can see by our two mutants, the 
HDL mutant and the G2E6 polar mutant that it only takes a small number of surface residues to 
largely determine the solubility of the protein.  We can also see that making a small number of 
Figure 16. 12.5% SDS Page Gel showing the elution products of C-terminal 
His6-tag, MBP fusion, huPON1 and its variants after being co-expressed with 
chaperone set DNA KJE7. 
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surface mutations that are far from the active site still can affect the activity.  Our mutants, 
though very soluble, had decreased activity by an unknown mechanism.  This problem of 
expressing human proteins in E. coli continues to be a great challenge in biochemistry and gene 
engineering. 
There is more than one way to achieve solubility as we have shown with our variants.  
The rational design by changing hydrophobic residues to polar or charged residues was a huge 
help in making huPON1 more soluble.  However, when fused with MBP, even wild-type 
huPON1 was soluble.  This is a large feat considering previous literature put the overall yield 
after expression and purification to be 5 mg from 12 L of fermentor prep, or ~450 µg per L of 
culture.
18
  Our yield of 2 mg/L from shake flask expression of huPON1 fused with MBP when 
co-expressed with molecular chaperones, DNA KJE7, far exceeds the previous amount.  The 
molecular chaperones helped increase the expression yield of huPON1 and its variants by 
helping fold the protein correctly in vivo.  This method also helped in the problem of truncation 
products.  By correctly folding, the protein will less likely aggregate and form inclusion bodies.  
Moving the His6-tag to the C-terminus of our protein also decreased the truncation products.  If 
for some reason the translation of our gene terminates early, then the translation of the His6-tag 
also will also be terminated.  The only problem with the C-terminal tag is cleavage of it through 
a TEV protease site.  This can, however, be changed through re-engineering of our pET11 
vector. 
Since we have combined multiple solubilizing techniques to express large amounts of 
huPON1 in E. coli, we now have to continue to try and improve the stability of this protein.  If 
we can screen for stability and activity, perhaps a fully functional, highly active huPON1 can be 
optimized with very limited immunological effects.  We can also continue optimizing the 
24 
 
purification conditions to obtain a more stable huPON1.  In any case, working with G2E6 and 
our soluble variants as models, we can try and pinpoint the mechanism of hydrolysis of 
organophosphates so huPON1 can work as an efficient catalytic bioscavenger. 
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